
Letter - Proprietary Name Review - Prevnar 13

 
 
Our STN: BLA 125324

Wyeth Pharmaceuticals, Inc.

Attention: Jack D. Love, Ph.D.
 401 N. Middletown Road
 Pearl River, NY 10965

Dear Dr. Love:

We have reviewed your submission dated March 31, 2009, to your biologics license application (BLA) for Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) requesting a proprietary name review.

In consultation with CBERs Advertising and Promotional Labeling Branch (APLB) we conclude that under the Federal Food, Drug, and Cosmetic Act and applicable regulations, your proposed proprietary name, Prevnar 13, is acceptable at this time.

If you have any questions, please contact either Regulatory Project Manager, LCDR Michael Smith, Ph.D., or CDR Colleen Sweeney, M.S., at (301)-827-3070.

Sincerely yours,

--signature--

Wellington Sun, M.D.
 Director
 Division of Vaccines and Related Products Applications
 Office of Vaccines Research and Review
 Center for Biologics Evaluation and Research
